Venous Invasion in Pancreatic Neuroendocrine Tumors Is Independently Associated With Disease-free Survival and Overall Survival.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
medline:
17
5
2023
pubmed:
6
4
2023
entrez:
5
4
2023
Statut:
ppublish
Résumé
In this study, we evaluated venous invasion and its association with survival in patients with resected pancreatic neuroendocrine tumor (PanNET). Surgical Pathology Archives were searched for pancreatectomies performed for PanNET between October 1, 2005, and December 31, 2019. Hematoxylin and eosin (H&E)-stained slides were evaluated for venous invasion, and Movat's stain was performed in all cases with no venous invasion detected on H&E stains. Pathology reports and electronic medical records were also reviewed. Venous invasion was identified in 23 of 145 (15.9%) cases on H&E stains, and Movat's stain identified additional 34 cases with venous invasion (39.3% overall). Orphan arteries with adjacent well-defined tumor nodules or subtle hyalinizing nodules in hyalinizing tumors are highly specific for venous invasion. In stage I-III cases (n=122), venous invasion was associated with larger tumor size, higher World Health Organization (WHO) tumor grade, perineural invasion, extrapancreatic extension, lymph node metastasis, and liver metastasis ( P <0.05). In univariate analyses, tumor size, WHO grade, venous invasion, perineural invasion, T stage, and lymph node metastasis all correlated with disease-free survival; however, only venous invasion was associated with worse disease-free survival in multivariate analyses ( P <0.01). In all-stage cases, venous invasion was the only attributor associated with worse overall survival in multivariate analyses ( P =0.03). In summary, venous invasion in PanNET can be histologically subtle, and Movat's stain can greatly increase the detection rate. More importantly, enhanced venous invasion by Movat's stain correlates independently with disease-free survival in patients with stage I-III tumors and overall survival in all-stage patients.
Identifiants
pubmed: 37017316
doi: 10.1097/PAS.0000000000002038
pii: 00000478-202306000-00004
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
678-685Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
Klimstra DS, Kloppel G, La Rosa S, et al. WHO Classification of Tumours Editorial Board. Classification of neuroendocrine neoplasms of the digestive system. WHO Classification of Tumors Digestive System Tumors, 5th ed. International Agency for Research on Cancer (IARC); 2019:16–19.
Taskin OC, Clarke CN, Erkan M, et al. Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication. J Gastrointest Oncol. 2020;11:548–558.
Emily K, Bergsland EAW, Rindi G, et al. Mahul B. Amin, Stephen B. Edge, Frederick L. Greene. Neuroendocrine tumors of the pancreas. AJCC Cancer Staging Manual, 8th ed. Springer; 2017:407–419.
Newland RC, Chan C, Chapuis PH, et al. Relative effects of direct spread, lymph node metastasis and venous invasion in relation to blood borne distant metastasis present at the time of resection of colorectal cancer. Pathology. 2020;52:649–656.
Kim HJ, Choi GS, Seo AN, et al. Prognostic value of venous invasion detected by elastin stain may surpass lymph node status in colon cancer. Dis Colon Rectum. 2021;64:955–963.
Westenend PJ, Meurs CJ, Damhuis RA. Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Pathol. 2005;58:196–201.
Lord AC, Knijn N, Brown G, et al. Pathways of spread in rectal cancer: a reappraisal of the true routes to distant metastatic disease. Eur J Cancer. 2020;128:1–6.
Thuluvath PJ. Vascular invasion is the most important predictor of survival in HCC, but how do we find it? J Clin Gastroenterol. 2009;43:101–102.
Shin J, Wood LD, Hruban RH, et al. Desmin and CD31 immunolabeling for detecting venous invasion of the pancreatobiliary tract cancers. PLoS One. 2020;15:e0242571.
Dawson H, Kirsch R, Driman DK, et al. Optimizing the detection of venous invasion in colorectal cancer: the ontario, Canada, experience and beyond. Front Oncol. 2014;4:354.
Abou-Alfa GK, Pawlik TM, Shindon J, et al. In: Mahul B. Amin, Stephen B. Edge , Frederick L. Greene, eds. Liver AJCC Cancer Staging Manual, 8th ed. Springer; 2017:287–293.
Yamada M, Sugiura T, Okamura Y, et al. Microscopic venous invasion in pancreatic cancer. Ann Surg Oncol. 2018;25:1043–1051.
Sari A, Cyr DP, Brar A, et al. Routine elastin staining in surgically resected colorectal cancer: impact on venous invasion detection and its association with oncologic outcomes. Am J Surg Pathol. 2022;46:200–212.
Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci. 2008;1131:225–234.
Royston D, Jackson DG. Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol. 2009;217:608–619.
Fujii T, Tabe Y, Yajima R, et al. Process of distant lymph node metastasis in colorectal carcinoma: implication of extracapsular invasion of lymph node metastasis. BMC Cancer. 2011;11:216.
Fujii T, Sutoh T, Morita H, et al. Vascular invasion, but not lymphatic invasion, of the primary tumor is a strong prognostic factor in patients with colorectal cancer. Anticancer Res. 2014;34:3147–3151.
Yano M, Shetty AS, Williams GA, et al. Qualitative imaging features of pancreatic neuroendocrine neoplasms predict histopathologic characteristics including tumor grade and patient outcome. Abdom Radiol (NY). 2022;47:3971–3985.
Chatterjee D, Trikalinos NA, Williams GA, et al. Intratumoral fibrosis and tumor growth pattern as prognostic factors in optimally resected pancreatic neuroendocrine neoplasms: an analysis of 168 cases. Pancreas. 2020;49:255–260.
Cienfuegos JA, Rotellar F, Salguero J, et al. A single institution’s 21-year experience with surgically resected pancreatic neuroendocrine tumors: an analysis of survival and prognostic factors. Rev Esp Enferm Dig. 2016;108:689–696.
Du B, Wang X, Zhang W, et al. Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis. ANZ J Surg. 2022;92:787–793.
Gao C, Fu X, Pan Y, et al. Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases. Dig Surg. 2010;27:197–204.
Aysal A, Agalar C, Egeli T, et al. Reconsideration of clinicopathologic prognostic factors in pancreatic neuroendocrine tumors for better determination of adverse prognosis. Endocr Pathol. 2021;32:461–472.
Genç CG, Falconi M, Partelli S, et al. Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol. 2018;25:2467–2474.
Tan QQ, Wang X, Yang L, et al. Predicting survival in non-functional pancreatic neuroendocrine tumours. ANZ J Surg. 2020;90:2026–2031.
Pulvirenti A, Javed AA, Landoni L, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors. Ann Surg. 2021;274:1051–1057.
Zhang P, Li YL, Qiu XD, et al. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study. World J Surg Oncol. 2019;17:66.
Marchegiani G, Landoni L, Andrianello S, et al. Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where? Neuroendocrinology. 2019;108:161–171.
Landoni L, Marchegiani G, Pollini T, et al. The evolution of surgical strategies for pancreatic neuroendocrine tumors (Pan-NENs): time-trend and outcome analysis from 587 consecutive resections at a high-volume institution. Ann Surg. 2019;269:725–732.
Zhang XF, Wu Z, Cloyd J, et al. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: results from the US Neuroendocrine Tumor Study Group. Surgery. 2019;165:548–556.
Ge W, Zhou D, Xu S, et al. Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors. Int J Surg. 2017;39:127–134.
Hong SM, Jung D, Kiemen A, et al. Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion. Mod Pathol. 2020;33:639–647.
Addeo P, d’Alessandro A, Averous G, et al. Macrovascular venous invasion of pancreatic neuroendocrine tumours: impact on surgical outcomes and survival. HPB (Oxford). 2019;21:653–661.
Han X, Xu X, Jin D, et al. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43:526–531.
Nanno Y, Toyama H, Otani K, et al. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology. 2016;16:882–887.